Overactive bladder pharmacotherapy: What does the future hold?

BJU International

Volumn 99, Issue SUPPL. 3, 2007, Pages 13-16

  Dmochowski, Roger R ^a,b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Capsaicin; Duloxetine; M3 receptors; Overactive bladder; Resiniferatoxin; Urgency; Warning time

Indexed keywords

BOTULINUM TOXIN A; CHOLINERGIC RECEPTOR BLOCKING AGENT; DARIFENACIN; MUSCARINIC M3 RECEPTOR ANTAGONIST; RESINIFERATOXIN; SOLIFENACIN; TOLTERODINE; TROSPIUM CHLORIDE;

BLADDER DISEASE; BLURRED VISION; CLINICAL TRIAL; COGNITIVE DEFECT; CONSTIPATION; HUMAN; INTERSTITIAL CYSTITIS; LOWER URINARY TRACT SYMPTOM; NEUROGENIC DETRUSOR OVERACTIVITY; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; OVERACTIVE BLADDER; PRIORITY JOURNAL; REVIEW; TACHYCARDIA; URGE INCONTINENCE; URINARY URGENCY; XEROSTOMIA;

FEMALE; FORECASTING; HUMANS; MALE; MUSCARINIC ANTAGONISTS; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE; XEROSTOMIA;

EID: 34247217084     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2007.06594.x     Document Type: Review

References (17)

1. Landis JR, Kaplan S, Swift S, Versi E. Impact of urge incontinence severity on drug treatment efficacy. International Continence Society 33rd Annual Congress, Florence, Italy. 2003: Abstract 118 available at www.icsoffice.org (accessed 3 November 2004)
2. Bowden A, Colman S, Sabounjian L, Sandage B, Schwiderski U, Zayed H. Psychometric validation of an urgency severity scale (IUSS) for patients with overactive bladder. International Continence Society 33rd Annual Congress, Florence, Italy. 2003: Abstract 119 available at www.icsoffice.org (accessed 3 November 2004)
3. Freeman R, Hill S, Millard R, Slack M, Sutherst J; Tolterodine Study Group. Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine. Obstet Gynecol 2003; 102: 605-11
4. Cardozo L, Prescott K, Serdarevic D, Skillem L. Can medication prolong warning time? International Continence Society 33rd Annual Congress, Florence, Italy. 2003: Abstract 74 available at www.icsoffice.org (accessed 3 November 2004)
5. Shabsigh R, Kaufman JM, Steidle C, Padma-Nathan H. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol 2004; 172: 658-63
6. Geraghty PB, Attwood D, Collett JH, Dandiker Y. Thein vitro release of some antimuscarinic drugs from monoolein/water lyotropic liquid crystalline gels. Pharm Res 1996; 13: 1265-71
7. 3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol 2004; 45: 420-9
8. Chapple CR, Rechberger T, Al-Shukri S et al.; YM-905 Study Group. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 2004; 93: 303-10
9. Chancellor MB, deGroat WC. Intravesical capsaicin and resiniferatoxin therapy: spicing up the ways to treat the overactive bladder. J Urol 1999; 162: 3-11
10. Holzer-Petsche U, Lembeck F. Systemic capsaicin treatment impairs the micturition reflex in the rat. Br J Pharmacol 1984; 83: 935-41
11. Yoshimura N, Erdman SL, Snider MW, de Groat WC. Effects of spinal cord injury on neurofilament immunoreactivity and capsaicin sensitivity in rat dorsal root ganglion neurons innervating the urinary bladder. Neuroscience 1998; 83: 633-43
12. Kawatani M, Whitney T, Booth AM, de Groat WC. Excitatory effect of substance P in parasympathetic ganglia of cat urinary bladder. Am J Physiol 1989; 257: R1450-6
13. Fowler CJ, Beck RO, Gerrard S, Betts CD, Fowler CG. Intravesical capsaicin for treatment of detrusor hyperreflexia. J Neurol Neurosurg Psychiatry 1994; 57: 169-73
14. Kim JH, Rivas DA, Shenot PJ et al. Intravesical resiniferatoxin for refractory detrusor hyperreflexia: a multicenter, blinded, randomized, placebo-controlled trial. J Spinal Cord Med 2003; 26: 358-63
15. Payne CK, Mosbaugh PG, Forrest JB et al.; ICOS RTX Study Group. Intravesical resiniferatoxin for the treatment of interstitial cystitis: a randomized, double-blind, placebo controlled trial. J Urol 2005; 173: 1590-4
16. Schurch B, De Sèze M, Denys P et al. Botulinum toxin A (Botox® ) in neurogenic urinary incontinence: results from a multi-centre randomized, controlled trial. International Continence Society 34th Annual Congress, Paris, France. 2004: Abstract 151 available at www.icsoffice.org (accessed 3 November 2004)
17. Schurch B, De Sèze M, Denys P et al.; Botox Detrusor Hyperreflexia Study Team. Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 2005; 174: 196-200